New research published in npj mental health research reported that specific brain network signals may reliably predict whether patients with major depression will respond to antidepressant treatment.
Major depressive disorder affects millions of people around the world, but doctors still don’t have the tools to determine which patients would benefit from antidepressants. Current treatments are largely trial and error, and it often takes several months to find out if a drug is working.
Scientists have long suspected that the brain’s “default mode network” – the system active during introspection and rumination – plays a central role in depression. But until now, no study has convincingly shown that patterns within this network can predict treatment outcome.
A research team led by Kaizhong Zheng and Liangjun Chen set out to test whether communication between two hubs of the default mode network, the medial prefrontal cortex (mPFC) and the posterior cingulate cortex (PCC), could serve as such a predictor. These areas are known to be involved in self-centered thinking and emotional regulation, and both are disrupted in depression.
To investigate this, the research team analyzed resting-state brain scans of a total of 4,271 participants across four datasets. The largest of these cohorts included 2,142 people diagnosed with major depression and 1,991 healthy people.
The sample included both newly diagnosed and recurrently depressed patients who had never taken antidepressants. Additional datasets tracked patients undergoing antidepressant medication or repetitive transcranial magnetic stimulation (rTMS), allowing the team to examine how brain connectivity correlated with treatment.
The research team used a technique called Granger causality analysis to measure the directional flow of information from the mPFC to the PCC. They found that those with recurrent depression had significantly reduced connectedness compared to both healthy participants and participants experiencing a first depressive episode who were not taking antidepressants. This reduction was also correlated with longer illness duration and previous antidepressant use.
Most strikingly, pre-treatment baseline signal predicted who would improve with treatment. The researchers noted that successful antidepressant treatment actually reduces coupling between the mPFC and PCC. More importantly, a machine learning model trained on patients’ baseline connectivity measurements was able to distinguish between prospective responders and non-responders with high accuracy, even before treatment began.
Baseline connectivity measures, but not initial severity of core depressive symptoms such as anhedonia and suicidal ideation, were also associated with eventual treatment improvement, suggesting that this reflects treatment-specific mechanisms rather than general illness severity.
Zheng and Chen concluded, “Despite the known pivotal role of the DMN in various cognitive and emotional processes, the DMN has not yet been targeted for therapeutic intervention. Our study reveals an important association between the DMN and treatment outcome and provides strong evidence for the feasibility of interventions targeting the DMN.”
Despite its promise, this study has limitations. For example, this study only investigated antidepressants and rTMS and did not include other treatments with distinct mechanisms, such as electroconvulsive therapy (ECT) or psychotherapy, which may indicate different patterns of brain connectivity.
The study, “Beyond symptoms of depression: Default mode network as a predictor of antidepressant response,” was authored by Kaizhong Zheng, Liangjun Chen, Huaning Wang, DIRECT consortium, Baojuan Li, and Badong Chen.
